BMS mAbs for COVID-19: real-time analysis

Download Image

Post

c19early.org

BMS mAbs for COVID-19

1 study with 210 patients

Serious outcome risk

BMS mAbs

Control

Significantly lower risk for progression.

COVID-19 BMS mAbs studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−36%

Hospitalization (1)−36%

Viral clearance (1)4%

RCTs (1)−36%

Early (1)−36%

00.511.5+

← BMS mAbs
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Aug 11 2024	Focosi, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268	Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
	Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date.
Aug 8 2024	Casadevall et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae408	Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship
	Review arguing against use of single monoclonal antibodies for COVID-19 treatment, particularly in immunosuppressed patients, due to the risk of rapidly selecting for resistant viral variants. Authors suggest that while monoclonal antibod..
May 6 2024	Corada et al., Pathogens & Immunity, doi:10.20411/pai.v9i1.660	Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
	17% lower progression (p=0.03), 20% faster recovery (p=0.19), and 4% improved viral clearance (p=0.45). RCT 211 outpatients with COVID-19 showing no significant difference in time to symptom improvement with subcutaneous BMS-986414 (C135-LS, ogalvibart) and BMS-986413 (C144-LS, crexavibart) monoclonal antibodies compared to placebo. There w..